JGC
PVLA icon

J. Goldman & Co’s Palvella Therapeutics PVLA Stock Holding History

J. Goldman & Co’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,692
Closed -$2.55M – 773
2025
Q3 		$2.55M Sell
40,692
-15,598
-28% -$696K 0.06% 262
2025
Q2 		$1.27M Buy
+56,290
New +$1.32M 0.03% 324

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Summit Partners Public Asset Management
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

J. Goldman & Co's PVLA Position: Q4 2025 in Review

J. Goldman & Co sold out of Palvella Therapeutics (PVLA) in Q4 2025, closing a stake of 40,692 shares — an estimated $2.55M sold.

J. Goldman & Co first reported a position in PVLA in Q2 2025 and held it in 2 quarters. The position peaked at $2.55M in Q3 2025. 140 funds tracked by Wall St. Rank hold PVLA as of Q4 2025.

  • J. Goldman & Co reported no remaining Palvella Therapeutics position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 40,692 Palvella Therapeutics shares in Q4 2025, an estimated $2.55M.
  • J. Goldman & Co first reported a position in Palvella Therapeutics in Q2 2025 and held it in 2 quarters.
  • J. Goldman & Co's Palvella Therapeutics position peaked at $2.55M in Q3 2025.
  • 140 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.